Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 16/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 16/20 | 0.64 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.64 |
| ▸ | NOS2 | P35228 | 4/20 | 0.55 |
| ▸ | NOS1 | P29475 | 3/20 | 0.55 |
| ▸ | NOS3 | P29474 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6206867 | 0.93 | SLC6A2 (0.61) | SLC6A2SLC6A4SLC6A3NOS2NOS1 | |
| Cadaverine Tartrate SCHEMBL5996582 | 0.92 | SLC6A4 (0.68) | SLC6A2SLC6A4SLC6A3CYP2D6KCNH2 | |
| SCHEMBL5996210 | 0.88 | SLC6A2 (0.67) | SLC6A2SLC6A4SLC6A3NOS2NOS1 | |
| SCHEMBL5997358 | 0.87 | SLC6A2 (0.71) | SLC6A2SLC6A4SLC6A3NOS2NOS1 | |
| SCHEMBL5994236 | 0.84 | NOS2 (0.71) | SLC6A2SLC6A4SLC6A3NOS2NOS1 | |
| SCHEMBL5993861 | 0.84 | SLC6A2 (0.64) | SLC6A2SLC6A4SLC6A3NOS2NOS1 | |
| SCHEMBL5995944 | 0.83 | SLC6A2 (0.63) | SLC6A2SLC6A4SLC6A3NOS2NOS1 | |
| SCHEMBL5998186 | 0.83 | SLC6A2 (0.64) | SLC6A2SLC6A4SLC6A3NOS2NOS1 | |
| SCHEMBL4498361 | 0.82 | SLC6A2 (0.65) | SLC6A2SLC6A4SLC6A3NOS2NOS1 | |
| SCHEMBL4482093 | 0.80 | SLC6A2 (0.66) | SLC6A2SLC6A4SLC6A3NOS2NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060079554-A1 | Inhibitors of monomine uptake | ELI LILLY AND COMPANY | 2006-04-13 | — | — | US | disclosed |
| EP-1569905-A2 | INHIBITORS OF MONOAMINE UPTAKE | ELI LILLY AND COMPANY (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004052858-A2 | INHIBITORS OF MONOAMINE UPTAKE | ELI LILLY AND COMPANY (US) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079554-A1 | Inhibitors of monomine uptake | SLC6A2, SLC18A2, SLC6A3 | SLC6A2 1/4885SLC6A4 4/4885SLC6A3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.